These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 25018885)

  • 1. Guillain-Barré Syndrome following Treatment with Sunitinib Malate.
    Kanaan Z; Kulairi Z; Titianu M; Saha S; Kumar S
    Case Rep Oncol Med; 2014; 2014():712040. PubMed ID: 25018885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guillain-Barré syndrome after treatment with sunitinib malate?
    Mulherin B; Loconte NK; Holen KD
    Oncology (Williston Park); 2008 Jan; 22(1):66-7, 70-1. PubMed ID: 18251284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute sunitinib neurotoxicity.
    Gulmez A; Dikilitas M; Elkiran ET; Harputluoglu H
    Cancer Treat Res Commun; 2021; 27():100366. PubMed ID: 33812180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST).
    Le Tourneau C; Raymond E; Faivre S
    Ther Clin Risk Manag; 2007 Jun; 3(2):341-8. PubMed ID: 18360643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.
    Adams VR; Leggas M
    Clin Ther; 2007 Jul; 29(7):1338-53. PubMed ID: 17825686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.
    Goodman VL; Rock EP; Dagher R; Ramchandani RP; Abraham S; Gobburu JV; Booth BP; Verbois SL; Morse DE; Liang CY; Chidambaram N; Jiang JX; Tang S; Mahjoob K; Justice R; Pazdur R
    Clin Cancer Res; 2007 Mar; 13(5):1367-73. PubMed ID: 17332278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current management of patients with gastrointestinal stromal tumor receiving the multitargeted tyrosine kinase inhibitor sunitinib.
    Pilotte AP
    Curr Med Res Opin; 2015; 31(7):1363-76. PubMed ID: 25912466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sunitinib malate for gastrointestinal stromal tumour in imatinib mesylate-resistant patients: recommendations and evidence.
    Younus J; Verma S; Franek J; Coakley N;
    Curr Oncol; 2010 Aug; 17(4):4-10. PubMed ID: 20697509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral administration of sunitinib malate for long-term survival of a patient with multiple lung metastases from renal leiomyosarcoma.
    Li X; Gao H; Tang C; Liu X
    Onco Targets Ther; 2016; 9():4753-6. PubMed ID: 27536137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins.
    Deprimo SE; Bello CL; Smeraglia J; Baum CM; Spinella D; Rini BI; Michaelson MD; Motzer RJ
    J Transl Med; 2007 Jul; 5():32. PubMed ID: 17605814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral adverse events in cancer patients treated with VEGFR-directed multitargeted tyrosine kinase inhibitors.
    Yuan A; Kurtz SL; Barysauskas CM; Pilotte AP; Wagner AJ; Treister NS
    Oral Oncol; 2015 Nov; 51(11):1026-1033. PubMed ID: 26403941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sunitinib malate for the treatment of renal cell carcinoma.
    Wood L
    Expert Opin Pharmacother; 2012 Jun; 13(9):1323-36. PubMed ID: 22607009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors.
    Blanke CD; Huse DM
    J Med Econ; 2010; 13(4):681-90. PubMed ID: 21067355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib.
    Chu TF; Rupnick MA; Kerkela R; Dallabrida SM; Zurakowski D; Nguyen L; Woulfe K; Pravda E; Cassiola F; Desai J; George S; Morgan JA; Harris DM; Ismail NS; Chen JH; Schoen FJ; Van den Abbeele AD; Demetri GD; Force T; Chen MH
    Lancet; 2007 Dec; 370(9604):2011-9. PubMed ID: 18083403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practical management of tyrosine kinase inhibitor-associated side effects in GIST.
    Joensuu H; Trent JC; Reichardt P
    Cancer Treat Rev; 2011 Feb; 37(1):75-88. PubMed ID: 20570050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.
    Rock EP; Goodman V; Jiang JX; Mahjoob K; Verbois SL; Morse D; Dagher R; Justice R; Pazdur R
    Oncologist; 2007 Jan; 12(1):107-13. PubMed ID: 17227905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 'CaboGIST'.
    Schöffski P; Mir O; Kasper B; Papai Z; Blay JY; Italiano A; Benson C; Kopeckova K; Ali N; Dileo P; LeCesne A; Menge F; Cousin S; Wardelmann E; Wozniak A; Marreaud S; Litiere S; Zaffaroni F; Nzokirantevye A; Vanden Bempt I; Gelderblom H
    Eur J Cancer; 2020 Jul; 134():62-74. PubMed ID: 32470848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors.
    Valle JW; Faivre S; Hubner RA; Grande E; Raymond E
    Cancer Treat Rev; 2014 Dec; 40(10):1230-8. PubMed ID: 25283354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sunitinib, a multitargeted tyrosine kinase inhibitor, in the management of gastrointestinal stromal tumor.
    George S
    Curr Oncol Rep; 2007 Jul; 9(4):323-7. PubMed ID: 17588358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
    Crona DJ; Keisler MD; Walko CM
    Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.